Introduction: In ret proto-oncogene (RET)-rearranged lung cancers, data on the frequency of brain metastases and, in particular, the outcomes of multikinase inhibitor therapy in patients with intracranial disease are not well characterized.
(p ¼ 0.0039) between RET-, ROS1-, and ALK receptor tyrosine kinase (ALK)-rearranged lung cancers, with RET intermediate between the other two groups. Although intracranial response data was not available in cohort A, the median progression-free survival of multikinase inhibitor therapy (cabozantinib, vandetanib, or sunitinib) in patients with brain metastases was 2.1 months (95% CI: 1.3-2.9 months, n ¼ 10). In cohort B, an intracranial response was observed in 2 of 11 patients (18%) treated with cabozantinib, vandetanib (± everolimus), ponatinib, or alectinib; the median overall progression-free survival (intracranial and extracranial) was 3.9 months (95% CI: 2.0-4.9 months).
Introduction
Ret proto-oncogene (RET) rearrangements are found in 1% to 2% of unselected patients with NSCLCs. 1 Similar to ALK receptor tyrosine kinase (ALK) and ROS1 rearrangements, these are often identified in younger patients with lung adenocarcinomas and a minimal to no history of prior cigarette smoking. RETdirected multikinase inhibitor therapy with drugs such as cabozantinib, vandetanib, and lenvatinib is active in a subset of patients with these tumors. [2] [3] [4] [5] Although lung cancers are known to frequently metastasize to the brain, the incidence of brain metastases in patients with RET-rearranged lung cancers, particularly in comparison to other driver-positive lung cancers, has not been well-defined. Furthermore, the clinical outcomes with multikinase inhibitor therapy in patients with brain metastases are poorly characterized. We set out to establish this data using a global, multicenter registry and a complementary bi-institutional dataset of RET-rearranged lung cancer patients.
Materials and Methods

Patients
The global RET registry was used as a platform to identify cases; a multicenter network of thoracic oncologists from 29 centers and 12 countries identified eligible patients (cohort A). 6 A separate, bi-institutional data set (Memorial Sloan Kettering Cancer Center, New York, New York, and the Massachusetts General Hospital, Boston, Massachusetts) was used as a complementary cohort (cohort B), given that data on the lifetime prevalence of brain metastases and intracranial response to therapy were not available in the former. Patients were identified under Institutional Review Board-approved waivers/protocols. For both cohorts, patients were eligible for inclusion if they had stage IV NSCLCs and a RET rearrangement identified by local molecular profiling (reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, DNA-based nextgeneration sequencing, or targeted RNA sequencing). A retrospective review of clinicopathologic and molecular features was performed. Response to therapy (overall and intracranial) was determined via the Response Evaluation Criteria in Solid Tumors version 1.1.
Treatment
Investigators administered multikinase inhibitor therapy with cabozantinib, vandetanib, vandetanib and everolimus, alectinib, ponatinib, and sunitinib off-label (treatment history as previously described 6 ). Patients who received cabozantinib included four subjects on a phase II trial (NCT01639508: patients were eligible if they had asymptomatic, untreated brain metastases; four patients met these criteria whereas the other 22 did not have untreated brain metastases at baseline). 2 A review of serial standard-of-care intracranial imaging was performed by a study-blinded radiologist.
Statistics
The cumulative incidence of brain metastasis was compared to a published dataset of patients with ALKand ROS1-rearranged lung cancers using the Gray's test. 7 Progression-free survival (PFS) and overall survival (OS) in patients with and without brain metastasis treated with multikinase inhibitors were determined using Kaplan-Meier estimates. Survival was measured from the date of treatment with the first multikinase inhibitor.
Results
Patients
A total of 114 patients with stage IV, RET-rearranged lung cancers were identified in cohort A (global RET registry). Information on the presence of brain metastases at the diagnosis of stage IV disease was available in 75 patients. In these 75 patients, the median age was 60 years (range, 28 to 86 years) and 45% of patients were female. Most patients were never-smokers (68%) with lung adenocarcinomas (96%). Kinesin family member 5B (KIF5B) was the most common upstream fusion partner (89%, Supplementary Table 1 ). Given that data on the lifetime prevalence of brain metastases and intracranial response to therapy were not available in cohort A, a separate bi-institutional cohort (cohort B, including 13 patients from cohort A for whom these data were available) was analyzed. Cohort B was composed of 71 patients. The median age was 58 years (range, 33 to 79 years) and 47% of patients were female. Similar to cohort A, most patients were never-smokers (69%) with lung adenocarcinomas (96%). KIF5B was the most common upstream partner (84%, Supplementary Table 2 ).
Frequency and Cumulative Incidence of Brain Metastases
The frequency of brain metastases at diagnosis in stage IV RET-rearranged lung cancers was 25% (95% confidence interval [CI]: 18%-32%; n ¼ 33 of 133) in all patients from both cohorts. The lifetime prevalence of brain metastases, including brain metastases at diagnosis, in patients with stage IV RET-rearranged lung cancers for whom data was available (cohort B) was 46% (95% CI: 34%-58%; n ¼ 33 of 71, Fig. 1A ). The cumulative incidence of brain metastases in patients from cohort B with stage IV RET-rearranged lung cancers and no history of brain metastases at diagnosis (n ¼ 54) was compared to a previously published cohort of patients with ROS1-rearranged (n ¼ 29) and ALKrearranged (n ¼ 98) lung cancers. We focused on ROS1-and ALK-rearranged lung cancers as comparators as these are the most common, targetable oncogenic fusions in NSCLC. The cumulative incidence of brain metastases was significantly different between groups (Gray's test, p ¼ 0.0039, Fig. 1B) , with RET-rearranged lung cancers intermediate between ALK-and ROS1-rearranged lung cancers. Pairwise comparisons revealed, however, that the cumulative incidence of brain metastases in RET-rearranged lung cancers was not different from ROS1-rearranged (p ¼ 0.051) or ALKrearranged (p ¼ 0.150) lung cancers; the cumulative incidence of brain metastases was higher in ALKcompared to ROS1-rearranged lung cancers (p ¼ 0.004).
Outcomes of Multikinase Inhibitor Therapy
In cohort A, 37 patients received a multikinase inhibitor with activity against RET (cabozantinib n ¼ 16, vandetanib n ¼ 9, sunitinib n ¼ 7, ponatinib n ¼ 1, nintedanib n ¼ 1, and other n ¼ 3). Active untreated brain metastases were present before multikinase inhibitor therapy in 10 of these patients. Whereas data on objective response to therapy are summarized in Supplementary Table 1 , data on intracranial response were not available. The median PFS in patients with brain metastases was 2.1 months (95% CI: 1.3-2.9 months). The median OS was 3.9 months (95% CI: 1.9-5.4). The median PFS and OS were not significantly different when compared to the remaining 27 patients without brain metastases (Fig. 2) .
In cohort B, data on intracranial response was available in 13 patients with brain metastases before the initiation of multikinase inhibitor therapy. These data, including information on fusion type and line of therapy, are summarized in Table 1 . Two patients (cases 1 and 9) received two or more multikinase inhibitors in sequence. Patients had either measurable and/or evaluable intracranial disease before therapy. All patients had active untreated disease at baseline except for case 9 for whom radiotherapy was administered to all sites of intracranial disease prior to sunitinib; progression of disease was the best intracranial response to therapy with sunitinib. No other patients received brain radiation or underwent intracranial surgery immediately before multikinase inhibitor therapy initiation.
In patients with measurable disease at baseline, a confirmed intracranial response was only observed in 2 of 11 cases (18%): 0 of 3 (0%) with cabozantinib, 0 of 3 (0%) with ponatinib, 1 of 2 (50%) with vandetanib and everolimus, 1 of 2 (50%) with alectinib, and 0 of 1 (0%) with vandetanib. Radiation therapy was eventually administered in 5 of 11 patients who were fit to receive treatment (45%; whole brain radiation in 2 cases, or stereotactic radiosurgery in 3 cases). Both responses were patients whose lung cancers harbored a coiled-coil domain containing 6 (CCDC6)-RET fusion. No intracranial responses were observed in KIF5B-RET fusion- positive tumors, consistent with select series showing lower rates of overall systemic response with KIF5B-RET-compared to non-KIF5B-RET-rearranged lung cancers.
1 Although hypothesis-generating, this requires further study in a larger cohort. The outcomes of cases with evaluable but non-measurable intracranial disease are detailed in Table 1 . The median overall PFS, reflecting both intracranial and extracranial disease control, was 3.9 months (95% CI: 2.0-4.9 months).
Discussion
In this series, we show that brain metastases frequently occur in RET-rearranged lung cancers. A quarter of patients have brain metastases at diagnosis of stage IV disease, and close to half of patients will develop brain metastases during their lifetime. The cumulative incidence of brain metastases in RET-rearranged lung cancer patients was intermediate between that of ALK-and ROS1-rearranged lung cancers when all three groups were compared.
Whereas durable intracranial responses to multikinase inhibitor therapy have been reported in RETrearranged lung cancers, we showed that overall clinical outcomes are poor, especially when compared to data on the activity of targeted therapies in ALK-and ROS1-rearranged lung cancers with metastatic disease to the brain. [8] [9] [10] [11] The intracranial response rate of multikinase RET inhibition was low, and the median PFS and OS times were short in patients with brain metastases. This relative difference echoes the decreased overall efficacy noted with multikinase RET-directed versus ALK-and ROS1-directed targeted therapy in RET-, ALK-, and ROS1-rearranged lung cancers, respectively, reflecting how the currently available multikinase inhibitors are suboptimal at targeting RET. 1 Before this report, data on the central nervous system activity of many single-agent multikinase inhibitors with anti-RET activity was not Note: The best objective response and the best intracranial response to multikinase inhibitor therapy (single agent or combination therapy) with activity against RET were determined by RECIST v1.1. a Refers to the best overall response (extracranial and intracranial). Overall response rate only in patients with measurable intracranial disease at baseline. Best intracranial response in non-target lesions (patient with evaluable but non-measurable disease).
d
Brain radiation administered before sunitinib, but first follow-up brain scan revealed progression of disease on sunitinib. TKI, tyrosine kinase inhibitor; CCDC6, coiled-coil domain containing 6; RET, ret proto-oncogene; KIF5B, kinesin family member 5B; FISHþ, positive RET fluorescence in situ break apart test; þ (under duration of therapy), indicates that therapy is ongoing; PR, partial response; SD, stable disease; PD, progression of disease; N/A, not applicable.
clearly defined. One exception to this is alectinib; however, data on intracranial outcomes was largely limited to ALK-rearranged lung cancers. Many RET inhibitors have substantial anti-angiogenic activity that some have hypothesized may contribute, in part, to response. 1 This series was limited by its retrospective nature and the inability to consistently assess all outcomes on both cohorts.
Novel RET-directed targeted therapy strategies are needed. The combination of vandetanib with everolimus has been postulated to increase brain penetrance 12 ; beyond the limited number of cases presented in this series, results of an ongoing trial of this combination (NCT01582191) will be informative. Furthermore, more selective RET inhibitors such as BLU-667 (NCT03037385) and LOXO-292 (NCT03157128) are currently in phase 1 testing. 13, 14 LOXO-292 showed preclinical activity in a mouse model harboring an orthotopically implanted intracranial RET-rearranged tumor; treatment with LOXO-292 resulted in intracranial disease control in 12 patients with baseline brain metastases on a phase I trial, including three of three confirmed intracranial responses in patients with measurable intracranial target lesions (Drilon et al., 15 ASCO Annual Meeting 2018), in addition to a nearcomplete intracranial response in a RET-rearranged lung cancer patient with multiple brain metastases on a compassionate use protocol. 16 Similarly, BLU-667 has shown preliminary intracranial antitumor activity in a RET-rearranged NSCLC patient enrolled in an ongoing phase I trial (Subbiah et al., 17 AACR Annual Meeting 2018).
We await the results of ongoing trials of these and future approaches. In addition, we encourage that trials of RET-directed therapy be designed to include baseline and serial brain imaging even in patients without a history of brain metastases. This will help further characterize not only response to therapy, but baseline intracranial disease, and patterns of disease progression in the central nervous system. Should novel strategies not be available to patients with RET-rearranged lung cancers that have metastasized to the central nervous system, best clinical judgement should be used to determine if single-agent multikinase inhibitor therapy could be complemented by local therapy such as surgery or radiation, either concurrently or in sequence.
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